HMG

Also known as: Human Menopausal Gonadotropin, Menotropin, Menopur

A combination of FSH and LH for fertility treatment.

Overview

HMG is a purified preparation containing both FSH and LH activity, originally derived from menopausal women's urine. Used to stimulate gonadal function in both sexes.

Mechanism of Action

FSH component stimulates follicle/sperm development. LH component supports steroidogenesis and final maturation. Combined action mimics natural gonadotropin function.

Pharmacokinetics

Half-life approximately 24 hours. Cumulative effects with daily dosing.

Dosing Protocols

Note: These are research protocols from literature. This is not medical advice.

1

Female Fertility

Dose

75-150 IU

Frequency

Daily

Duration

7-12 days

Monitor follicle development

2

Male Infertility

Dose

75-150 IU

Frequency

3x weekly

Duration

3-6 months

Combined with HCG

Stacking Recommendations

Peptides that may be combined based on complementary mechanisms in research settings.

Rationale: Complete fertility support

Synergy: FSH/LH plus LH-like trigger

Research Areas

Female InfertilityMale InfertilityIVF ProtocolsHypogonadism

Key Research Findings

  • 1Effective for ovulation induction
  • 2Used in IVF stimulation protocols
  • 3Can restore spermatogenesis in hypogonadal men
  • 4Well-established fertility treatment

Side Effects & Contraindications

Reported Side Effects

  • OHSS (females)
  • Injection site reactions
  • Multiple pregnancy
  • Gynecomastia (males)

Contraindications

  • Ovarian cysts
  • Unexplained uterine bleeding
  • Sex hormone-dependent tumors

Safety Considerations

Risk of ovarian hyperstimulation syndrome (OHSS) in females. Multiple pregnancy risk. Monitor with ultrasound and hormone levels.

Storage Requirements

Refrigerate at 2-8C

Scientific References

Quick Reference

Sequence
Glycoprotein mixture (FSH + LH)
Molecular Weight
~30,000 g/mol each
Half-Life
~24 hours
Bioavailability
High (IM, SC)
Research Stage
approved
Administration
Intramuscular or subcutaneous